Islet transplant for type 1 diabetes after kidney transplant
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests whether transplanting insulin-producing “islet” cells can better control blood sugar in people who have already received a kidney transplant. It’s mainly for adults with type 1 diabetes whose body is no longer making enough insulin, while they are on kidney-transplant medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 to 68 and can sign consent and follow study visits.
- You have type 1 diabetes that started before age 40 and you needed insulin for over 5 years; your age plus insulin duration must total over 28.
- Your body’s insulin-making ability is very low (very low C-peptide on a special meal test at 60 and 90 minutes).
- You have had a kidney transplant either more than 3 months ago or will get islet and kidney transplant from the same donor within 72 hours; you’re on stable anti-rejection medicines (tacrolimus and/or other listed meds) with low-dose prednisone if used.
- Your kidney function is stable enough for the trial (creatinine not much worse than your usual over the prior 3 months), and you don’t have new high urine protein after transplant.
- You meet key limits: weight 90 kg or less and BMI 30 or less; blood pressure controlled; no untreated unstable eye disease (proliferative retinopathy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether transplanting insulin-producing islet cells can improve blood sugar control and reduce severe low blood sugar in people with “brittle” type 1 diabetes. It’s meant for adults with long-standing insulin dependence and troublesome, hard-to-control hypoglycemia.
This trial tests a new treatment made from pig pancreatic cells (called OPF-310) that are placed under the skin to help control blood sugar in people with type 1 diabetes. It is for those whose diabetes is difficult to manage and who have dangerous low blood sugar episodes.
This trial looks at whether adding gastrin can improve outcomes after an islet cell transplant for people with type 1 diabetes. It may help some participants achieve better blood sugar control, but it also requires close follow-up and immune-suppressing medications to protect the new cells.
This trial tests a two-step transplant approach using immune-related stem cells and islet (pancreas insulin–making) cells in children and teens who have type 1 diabetes caused by a genetic immune problem. It aims to improve insulin control and protect other organs that are being affected by their immune system.
This study tests a new treatment called E-islet 01, which may help people with type 1 diabetes who have very low natural insulin production and have had dangerous low blood sugar events. The goal is to see if it is safe and can reduce those episodes.
This trial tests whether transplanting your own insulin-making cells (islets) can help control blood sugar if you have type 2 diabetes and your pancreas is not making enough insulin. The goal is to reduce or stop your need for insulin injections.
Hear when a new Diabetes Mellitus, Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.